Description
The histone deacetylase (HDAC) inhibitor vorinostat has received significant attention in recent years as an ‘epigenetic’ drug used to treat solid tumors. However, its mechanisms of action are not entirely understood, particularly with regard to its interaction with the aberrations in 3D nuclear structure that accompany neoplastic progression.
Copyright Statement
Reuse Permissions
Download count: 0
Details
Contributors
- Nandakumar, Vivek (Author)
- Hansen Katdare, Nanna (Author)
- Glenn, Honor (Author)
- Han, Jessica (Author)
- Helland, Stephanie (Author)
- Hernandez, Kathryn (Author)
- Senechal, Patti (Author)
- Johnson, Roger (Author)
- Bussey, Kimberly J. (Author)
- Meldrum, Deirdre (Author)
- Ira A. Fulton Schools of Engineering (Contributor)
Date Created
The date the item was original created (prior to any relationship with the ASU Digital Repositories.)
2016-08-09
Resource Type
Collections this item is in
Identifier
- Digital object identifier: 10.1038/srep30593
- Identifier TypeInternational standard serial numberIdentifier Value2045-2322
Note
- The final version of this article, as published in Scientific Reports, can be viewed online at: http://www.nature.com/articles/srep30593, opens in a new window
Citation and reuse
Cite this item
This is a suggested citation. Consult the appropriate style guide for specific citation guidelines.
Nandakumar, V., Hansen, N., Glenn, H. L., Han, J. H., Helland, S., Hernandez, K., . . . Meldrum, D. R. (2016). Vorinostat differentially alters 3D nuclear structure of cancer and non-cancerous esophageal cells. Scientific Reports, 6(1). doi:10.1038/srep30593